Repeatability of Quantitative


Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
09 2020
Historique:
received: 26 09 2019
accepted: 08 01 2020
pubmed: 12 1 2020
medline: 6 3 2021
entrez: 12 1 2020
Statut: ppublish

Résumé

Quantitative evaluation of radiolabeled prostate-specific membrane antigen (PSMA) PET scans may be used to monitor treatment response in patients with prostate cancer (PCa). To interpret longitudinal differences in PSMA uptake, the intrinsic variability of tracer uptake in PCa lesions needs to be defined. The aim of this study was to investigate the repeatability of quantitative PET/CT measurements using

Identifiants

pubmed: 31924729
pii: jnumed.119.236075
doi: 10.2967/jnumed.119.236075
pmc: PMC7456167
doi:

Substances chimiques

2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 0
Urea 8W8T17847W
Lysine K3Z4F929H6

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1320-1325

Informations de copyright

© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Références

J Nucl Med. 2020 Feb;61(2):210-216
pubmed: 31481580
J Nucl Med. 2016 May;57(5):721-7
pubmed: 26697964
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024
pubmed: 28283702
Prostate Cancer Prostatic Dis. 2016 Sep;19(3):223-30
pubmed: 27136743
Phys Med Biol. 2014 Jul 21;59(14):3843-59
pubmed: 24955921
Nucl Med Mol Imaging. 2018 Dec;52(6):420-429
pubmed: 30538773
Eur Urol. 2016 Dec;70(6):926-937
pubmed: 27363387
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1344-1361
pubmed: 29500480
Neuroimage. 2008 Feb 15;39(4):1570-84
pubmed: 18077187
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Nucl Med. 2014 Sep;55(9):1417-23
pubmed: 24970910
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
J Nucl Med. 2019 Aug;60(8):1111-1117
pubmed: 30630941
Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):602-612
pubmed: 29185010
Hum Pathol. 2007 May;38(5):696-701
pubmed: 17320151
Mol Imaging Biol. 2020 Feb;22(1):15-17
pubmed: 31624994
J Nucl Med. 2018 Oct;59(10):1516-1523
pubmed: 29626121
EJNMMI Res. 2019 Jul 30;9(1):70
pubmed: 31363939
J Labelled Comp Radiopharm. 2016 Sep;59(11):439-50
pubmed: 27470935
EJNMMI Res. 2018 Apr 12;8(1):30
pubmed: 29651565
Clin Cancer Res. 2011 Dec 15;17(24):7645-53
pubmed: 22042970
J Nucl Med. 2019 Dec;60(12):1730-1735
pubmed: 31000583

Auteurs

Bernard H E Jansen (BHE)

Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands bh.jansen@amsterdamumc.nl.
Department of Urology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands.

Matthijs C F Cysouw (MCF)

Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands.
Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands.

André N Vis (AN)

Department of Urology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands.

Reindert J A van Moorselaar (RJA)

Department of Urology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands.

Jens Voortman (J)

Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands.

Yves J L Bodar (YJL)

Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands.
Department of Urology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands.

Patrick R Schober (PR)

Department of Anesthesiology, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands; and.

N Harry Hendrikse (NH)

Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands.
Department of Clinical Pharmacology and Pharmacy, Cancer Center Amsterdam, Amsterdam University Medical Center, VU University, Amsterdam, The Netherlands.

Otto S Hoekstra (OS)

Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands.

Ronald Boellaard (R)

Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands.

D E Oprea-Lager (DE)

Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH